PH12014502041A1 - Heterocyclyl compounds as mek inhibitors - Google Patents

Heterocyclyl compounds as mek inhibitors

Info

Publication number
PH12014502041A1
PH12014502041A1 PH12014502041A PH12014502041A PH12014502041A1 PH 12014502041 A1 PH12014502041 A1 PH 12014502041A1 PH 12014502041 A PH12014502041 A PH 12014502041A PH 12014502041 A PH12014502041 A PH 12014502041A PH 12014502041 A1 PH12014502041 A1 PH 12014502041A1
Authority
PH
Philippines
Prior art keywords
compounds
mek inhibitors
heterocyclyl compounds
formula
present disclosure
Prior art date
Application number
PH12014502041A
Other languages
English (en)
Other versions
PH12014502041B1 (en
Inventor
Dave Bhavesh
Banerjee Rakesh Kumar
Phukan Samiron
Khoje Abhijit Datta
Hangarge Rajkumar
Jadhav Jitendra Sambhaji
Venkata P Palle
Kamboj Rajender Kumar
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12014502041(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of PH12014502041B1 publication Critical patent/PH12014502041B1/en
Publication of PH12014502041A1 publication Critical patent/PH12014502041A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
PH12014502041A 2012-03-14 2014-09-12 Heterocyclyl compounds as mek inhibitors PH12014502041A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN288KO2012 2012-03-14
PCT/IB2013/051908 WO2013136249A1 (en) 2012-03-14 2013-03-11 Heterocyclyl compounds as mek inhibitors

Publications (2)

Publication Number Publication Date
PH12014502041B1 PH12014502041B1 (en) 2014-11-24
PH12014502041A1 true PH12014502041A1 (en) 2014-11-24

Family

ID=47997632

Family Applications (2)

Application Number Title Priority Date Filing Date
PH12014502041A PH12014502041A1 (en) 2012-03-14 2014-09-12 Heterocyclyl compounds as mek inhibitors
PH12014502040A PH12014502040A1 (en) 2012-03-14 2014-09-12 Heterocyclyl compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
PH12014502040A PH12014502040A1 (en) 2012-03-14 2014-09-12 Heterocyclyl compounds

Country Status (35)

Country Link
US (5) US9573944B2 (2)
EP (2) EP2834237B1 (2)
JP (3) JP6093384B2 (2)
KR (4) KR20140138910A (2)
CN (4) CN107698585A (2)
AP (2) AP3859A (2)
AU (4) AU2013234014B2 (2)
BR (1) BR112014022713B1 (2)
CA (2) CA2865164C (2)
CL (2) CL2014002412A1 (2)
CO (2) CO7170131A2 (2)
CR (2) CR20140464A (2)
CU (2) CU24272B1 (2)
DK (2) DK2834237T3 (2)
DO (2) DOP2014000204A (2)
EA (2) EA028232B1 (2)
ES (2) ES2684517T3 (2)
GE (2) GEP201706774B (2)
GT (2) GT201400195A (2)
IL (2) IL234559A (2)
IN (2) IN2014MN01754A (2)
MA (2) MA37405A1 (2)
MX (3) MX355526B (2)
MY (2) MY175950A (2)
NI (2) NI201400107A (2)
NZ (2) NZ629442A (2)
PE (2) PE20141974A1 (2)
PH (2) PH12014502041A1 (2)
PL (1) PL2834237T3 (2)
SG (2) SG11201405006PA (2)
TN (2) TN2014000357A1 (2)
TR (1) TR201811976T4 (2)
UA (2) UA114906C2 (2)
WO (2) WO2013136249A1 (2)
ZA (1) ZA201406186B (2)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
KR20140138910A (ko) 2012-03-14 2014-12-04 루핀 리미티드 헤테로사이클릴 화합물
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
BR112016007396B1 (pt) * 2013-10-25 2021-01-19 Shanghai Hengrui Pharmaceutical Co., Ltd. Composto de fórmula (ii), seu processo de preparação e seu uso, composto de fórmula(iia) e composição farmacêutica
WO2016009306A1 (en) * 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
WO2016035008A1 (en) * 2014-09-04 2016-03-10 Lupin Limited Pyridopyrimidine derivatives as mek inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
JP7219218B2 (ja) 2016-12-22 2023-02-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のベンジルアミノ置換キナゾリンおよびｓｏｓ１阻害剤としての誘導体
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
RS64167B1 (sr) 2017-12-21 2023-05-31 Boehringer Ingelheim Int Benzilamino supstituisani piridopirimidinoni i derivati kao sos1 inhibitori
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
AU2020296914A1 (en) 2019-06-19 2021-12-23 Boehringer Ingelheim International Gmbh Anticancer combination therapy
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022001678A2 (pt) * 2019-07-30 2022-05-03 Edvince Ab Inibidor mek, uso de um inibidor mek, método de tratar ou reduzir o risco de desenvolver um acidente vascular cerebral em um sujeito, composição, e, kit de partes
EP3797899A1 (de) 2019-09-27 2021-03-31 Primetals Technologies Austria GmbH Vorrichtung und verfahren zum erkennen von einer bewegung eines körpers in einer industrieanlage
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021245055A1 (en) 2020-06-02 2021-12-09 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TWI825637B (zh) * 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
WO2022214594A1 (en) 2021-04-09 2022-10-13 Boehringer Ingelheim International Gmbh Anticancer therapy
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
JP2024514879A (ja) * 2021-04-16 2024-04-03 イケナ オンコロジー， インコーポレイテッド Ｍｅｋ阻害剤及びその使用
EP4346826A4 (en) 2021-05-27 2025-04-30 Mirati Therapeutics, Inc. COMBINATION THERAPIES
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2023099624A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US20250129096A1 (en) 2021-12-01 2025-04-24 Boehringer Ingelheim Int'l GmbH Corp. Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US20250145608A1 (en) 2021-12-01 2025-05-08 Boehringer Ingelheim Int'l GmbH Corp. Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
JP2024543982A (ja) 2021-12-01 2024-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング がんの処置のための縮環２－アミノ－３－シアノチオフェン及び誘導体
US20250313553A1 (en) 2021-12-01 2025-10-09 Boehringer Ingelheim Int'l GmbH Corp. Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN114573581B (zh) * 2022-03-30 2023-09-01 沈阳药科大学 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
CN114456166B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114573582B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
IL316768A (en) 2022-05-25 2025-01-01 Ikena Oncology Inc MEK inhibitors and their uses
JP2024047569A (ja) * 2022-09-26 2024-04-05 ファイザー・インク Ｍｅｋ阻害剤としての３，４－ジヒドロ－２，７－ナフチリジン－１，６（２ｈ，７ｈ）－ジオン
EP4719603A1 (en) 2023-05-30 2026-04-08 Boehringer Ingelheim International GmbH Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
UA72612C2 (en) * 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
ES2251677T3 (es) * 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
CA2546353A1 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
AU2005252110B2 (en) * 2004-06-11 2008-09-04 Shionogi & Co., Ltd. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer
BRPI0925050A2 (pt) 2009-04-21 2015-08-04 Novartis Ag Compostos heterocíclicos como inibidores de mek
KR20140138910A (ko) * 2012-03-14 2014-12-04 루핀 리미티드 헤테로사이클릴 화합물

Also Published As

Publication number Publication date
PH12014502040B1 (en) 2014-11-24
SG11201405006PA (en) 2014-10-30
IL234560A (en) 2017-06-29
EP2834237A1 (en) 2015-02-11
US20160331753A1 (en) 2016-11-17
CA2865167C (en) 2019-08-06
CA2865164A1 (en) 2013-09-19
US20170112840A1 (en) 2017-04-27
PH12014502040A1 (en) 2014-11-24
SG11201405007QA (en) 2014-10-30
CN104271577A (zh) 2015-01-07
ZA201406186B (en) 2016-06-29
JP6431770B2 (ja) 2018-11-28
CR20140463A (es) 2014-11-28
CU24335B1 (es) 2018-04-03
KR20190073597A (ko) 2019-06-26
NI201400108A (es) 2014-11-28
AP3859A (en) 2016-10-31
MA37405A1 (fr) 2016-03-31
JP2015514056A (ja) 2015-05-18
MX355526B (es) 2018-04-20
HK1202538A1 (en) 2015-10-02
AU2017200493B2 (en) 2018-03-29
EA028232B1 (ru) 2017-10-31
ES2684517T3 (es) 2018-10-03
MX2014010928A (es) 2015-04-10
PH12014502041B1 (en) 2014-11-24
EP2834236B1 (en) 2019-05-22
CL2014002411A1 (es) 2015-04-06
AU2018202568B2 (en) 2019-05-09
CO7160029A2 (es) 2015-01-15
CN108383836A (zh) 2018-08-10
AP2014008009A0 (en) 2014-10-31
EP2834236A1 (en) 2015-02-11
TN2014000357A1 (en) 2015-12-21
DOP2014000204A (es) 2015-02-15
EA201491671A1 (ru) 2014-12-30
UA114907C2 (uk) 2017-08-28
NZ629442A (en) 2016-12-23
JP6630771B2 (ja) 2020-01-15
US9573944B2 (en) 2017-02-21
CN104203947A (zh) 2014-12-10
CU20140109A7 (es) 2014-11-27
JP6093384B2 (ja) 2017-03-08
TR201811976T4 (tr) 2018-09-21
AU2013234014A1 (en) 2014-09-25
EA029768B1 (ru) 2018-05-31
GEP201706774B (en) 2017-11-27
AU2018202568A1 (en) 2018-05-10
IN2014MN01755A (2) 2015-07-03
DK2834236T3 (da) 2019-08-26
JP2015509975A (ja) 2015-04-02
AU2013234009A1 (en) 2014-09-25
UA114906C2 (uk) 2017-08-28
AP2014008008A0 (en) 2014-10-31
MY174188A (en) 2020-03-12
US20150299186A1 (en) 2015-10-22
GT201400196A (es) 2017-09-28
US9428499B2 (en) 2016-08-30
CO7170131A2 (es) 2015-01-28
WO2013136254A1 (en) 2013-09-19
PL2834237T3 (pl) 2018-11-30
CN107698585A (zh) 2018-02-16
ES2741896T3 (es) 2020-02-12
AU2017200493A1 (en) 2017-02-16
BR112014022713B1 (pt) 2021-09-08
KR20190100472A (ko) 2019-08-28
MX355474B (es) 2018-04-16
AU2013234014B2 (en) 2017-02-02
MX366426B (es) 2019-07-08
US20150133424A1 (en) 2015-05-14
CL2014002412A1 (es) 2015-03-06
US20170101408A1 (en) 2017-04-13
US9555035B2 (en) 2017-01-31
CR20140464A (es) 2014-11-28
BR112014022713A2 (2) 2017-06-20
NZ629432A (en) 2017-01-27
AU2013234009B2 (en) 2016-10-27
NI201400107A (es) 2014-11-26
CN108383836B (zh) 2021-11-12
EP2834237B1 (en) 2018-06-06
MY175950A (en) 2020-07-16
TN2014000356A1 (en) 2015-12-21
WO2013136249A1 (en) 2013-09-19
EA201491672A1 (ru) 2014-12-30
DK2834237T3 (en) 2018-08-27
AP3834A (en) 2016-09-30
MX2014010925A (es) 2015-04-10
GT201400195A (es) 2017-11-09
US9969731B2 (en) 2018-05-15
KR102241111B1 (ko) 2021-04-15
HK1206020A1 (en) 2015-12-31
GEP201706671B (en) 2017-05-25
US9827247B2 (en) 2017-11-28
PE20141974A1 (es) 2014-12-12
CA2865167A1 (en) 2013-09-19
KR20140138911A (ko) 2014-12-04
CU20140110A7 (es) 2014-11-27
DOP2014000203A (es) 2015-02-15
PE20141973A1 (es) 2014-12-12
KR102240101B1 (ko) 2021-04-14
CA2865164C (en) 2021-06-08
CU24272B1 (es) 2017-08-08
KR20140138910A (ko) 2014-12-04
MA37400B1 (fr) 2019-11-29
IL234559A (en) 2017-06-29
JP2018115215A (ja) 2018-07-26
MA37400A1 (fr) 2016-05-31
IN2014MN01754A (2) 2015-07-03

Similar Documents

Publication Publication Date Title
PH12014502041A1 (en) Heterocyclyl compounds as mek inhibitors
MX360634B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
IN2014DN09434A (2)
PH12014502524B1 (en) Carboxylic acid compounds
EA201201680A1 (ru) Морфолинопиримидины и их применение в терапии
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
MD20140063A2 (ro) Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
EA201591195A1 (ru) Новые хинолоновые производные
IN2014MN02598A (2)
IN2015DN01156A (2)
EA201492204A1 (ru) Нуклеозиды на основе урацила и спирооксетана
IN2015DN01119A (2)
EA201390984A1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
EA201600434A1 (ru) Применение производных бензимидазолпролина
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
EA201491878A1 (ru) Замещенные ксантиновые производные
UA111851C2 (uk) Сполуки піридазинону та їх використання як інгібіторів daao